Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Raul Soikes"'
Autor:
Christian Wichmann, Andrew Scott, Fiona Scott, Ingrid Burvenich, Alexander McDonald, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/01b02f2da1a94413b01d9c610d15a554
Autor:
Stefan K. Barta, Daniel J. Landsburg, Sonali M. Smith, Raul Soikes, Yasuhiro Oki, Robert E. Martell, Kevin R. Kelly, Gideon Bosker, Ivana N. Micallef, Radhakrishnan Ramchandren, Swaminathan P. Iyer, Andrea Califano, Reinhard von Roemeling, Yao Shen, Elizabeth Martinez, Mariano J. Alvarez, Jefferson Parker, Connie Lee Batlevi, Don A. Stevens
Publikováno v:
British journal of haematologyReferences. 195(2)
Fimepinostat (CUDC-907), a first-in-class oral small-molecule inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high-grade B-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e11855505f8f6a5edd240d1717ca89
https://pubmed.ncbi.nlm.nih.gov/34341990
https://pubmed.ncbi.nlm.nih.gov/34341990
Autor:
Christina A. von Roemeling, Bently P. Doonan, Lan Hoang-Minh, Han W. Tun, Elizabeth Martinez, Raul Soikes, Reinhard von Roemeling, Duane A. Mitchell
Publikováno v:
Molecular Cancer Therapeutics. 20:P243-P243
Background: Central nervous system (CNS) lymphoma, both primary and secondary disease, carries the worst prognosis of all Non-Hodgkin’s lymphoma with a 5 year survival of less than 30% with current therapeutic options. Recent studies have shown con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bad0bfba5cf256ac83ca95900758d483
https://doi.org/10.1158/1535-7163.targ-21-p243
https://doi.org/10.1158/1535-7163.targ-21-p243
Autor:
Ingrid Burvenich, Steven Angelides, Fiona Scott, Alexander McDonald, Andrew M. Scott, Christian Wichmann, Raul Soikes, Nancy Guo, Angela Rigopoulos, Reinhard von Roemeling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundVISTA (V-domain Ig suppressor of T-cell activation) inhibits anti-tumour immune responses. The Investigational product CI-8993 is a fully human IgG1k monoclonal antibody that binds specifically to this immune checkpoint molecule. Phase I sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dad23eb1b98ce2686dca13e5290dd30
https://doi.org/10.1136/jitc-2021-sitc2021.324
https://doi.org/10.1136/jitc-2021-sitc2021.324